EGLN3抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P00648(EGLN3 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The EGLN3 antibody is a crucial tool for studying the EGLN family of prolyl hydroxylases, particularly EGLN3 (also known as PHD3 or HIF-PH3), which plays a central role in cellular oxygen sensing. EGLN3 regulates the stability of hypoxia-inducible factors (HIFs) by hydroxylating specific proline residues on HIF-α subunits (HIF-1α, HIF-2α), marking them for proteasomal degradation via the VHL ubiquitin ligase complex. This oxygen-dependent process is vital for adaptive responses to hypoxia, angiogenesis, and metabolic reprogramming. Dysregulation of EGLN3 is implicated in cancers, ischemic diseases, and metabolic disorders, with its expression varying across tissues (e.g., heart, brain, liver).

The EGLN3 antibody enables researchers to detect and quantify EGLN3 protein levels in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). It aids in exploring EGLN3’s role in pathological contexts, such as tumor progression (where it may act as a tumor suppressor or promoter depending on cancer type) or ischemic injury. High-quality EGLN3 antibodies are validated for specificity, often using knockout controls, to ensure reliable detection of the ~24-28 kDa protein. Such tools are essential for advancing studies on hypoxia-related pathways and evaluating EGLN3 as a therapeutic target.